FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
MANHASSET, NY
What changed
NIH R01 · $0.4M · Cellular interactions between TGF-beta pathway members and epigenetic regulators in liver and gastrointestinal cancers
Mar 2025Grant renewalMar 26, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 16 out of 100, unchanged since the last recompute.
Little recent filing activity, or the events on file have decayed.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Grant
R01 · $419k · non-dilutive
Jul 18, 2018FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI MISHRA, LOPA · NCI · award ends Mar 31, 2029 · Cellular interactions between TGF-beta pathway members and epigenetic regulators in liver and gastrointestinal cancers
NIH RePORTER · NIH RePORTER 11067815 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources